Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2022 21:38 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused...
November 17, 2022 16:24 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused...
November 10, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Reports Third Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
November 09, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
September 28, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,...
August 31, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
August 11, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Reports Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
May 25, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Private Placement Financing of $50 Million

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
May 23, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
May 11, 2022 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Reports First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...